Advertisement

Hepatic Coagulopathy: Intricacies and Challenges

  • Rakhee Kar
Chapter

Abstract

Liver is an elegant factory which synthesizes several plasma proteins, transport proteins, and most of the clotting factors to name just a few of its immense synthetic function. Virtually every arm of the complex hemostatic pathway gets deranged in liver disease. Hence, it is quite natural to find abnormal tests of hemostasis in patients with chronic liver disease (CLD). A bleeding as well as a clotting tendency does exist simultaneously in liver disease. These are due to a set of complex and multifactorial process leading to a state of rebalanced hemostasis in stable cirrhosis patients [1].

Keywords

Chronic liver disease (CLD) Coagulopathy Hemostasis Thrombocytopenia Rebalanced hemostasis 

References

  1. 1.
    Caldwell SH. Management of coagulopathy in liver disease. Gastroenterol Hepatol (N Y). 2014;10(5):330–2.Google Scholar
  2. 2.
    Sharara AI, Rockey DC. Gastroesophageal variceal hemorrhage. N Engl J Med. 2001;345(9):669–81.CrossRefGoogle Scholar
  3. 3.
    Tripodi A, Mannucci PM. Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research. J Hepatol. 2007;46:727–33.CrossRefGoogle Scholar
  4. 4.
    Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F, Weksler B, Esteban R. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48(6):1000–7.CrossRefGoogle Scholar
  5. 5.
    Hugenholtz GG, Porte RJ, Lisman T. The platelet and platelet function testing in liver disease. Clin Liver Dis. 2009;13(1):11–20.CrossRefGoogle Scholar
  6. 6.
    Trotter JF. Coagulation abnormalities in patients who have liver disease. Clin Liver Dis. 2006;10:665–78.CrossRefGoogle Scholar
  7. 7.
    Hollestelle MJ, Thinnes T, Crain K, Stiko A, Kruijt JK, van Berkel TJ, et al. Tissue distribution of factor VIII gene expression in vivo—a closer look. Thromb Haemost. 2001;86:855–61.CrossRefGoogle Scholar
  8. 8.
    Ben-Ari Z, Osman E, Hutton RA, et al. Disseminated intravascular coagulation in liver cirrhosis: fact or fiction? Am J Gastroenterol. 1999;94:2977–82.CrossRefGoogle Scholar
  9. 9.
    Ng VL. Liver disease, coagulation testing, and hemostasis. Clin Lab Med. 2009;29:265–82.CrossRefGoogle Scholar
  10. 10.
    Lisman T, Leebeek FWG, de Groot PG. Haemostatic abnormalities in patients with liver disease. J Hepatol. 2002;37:280–7.CrossRefGoogle Scholar
  11. 11.
    Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Iannaccone L, D’Andrea G, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology. 2000;31:345–8.CrossRefGoogle Scholar
  12. 12.
    Tripodi A. Tests of coagulation in liver disease. Clin Liver Dis. 2009;13:55–61.CrossRefGoogle Scholar
  13. 13.
    Lisman T, Leebeek FW, Mosnier LO, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology. 2001;121:131–9.CrossRefGoogle Scholar
  14. 14.
    Colucci M, Binetti BM, Branca MG, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology. 2003;38:230–7.CrossRefGoogle Scholar
  15. 15.
    Smalberg JH, Leebeek FWG. Superimposed coagulopathic conditions in cirrhosis: infection and endogenous heparinoids, renal failure, and endothelial dysfunction. Clin Liver Dis. 2009;13:33–42.CrossRefGoogle Scholar
  16. 16.
    Violi F, Leo R, Vezza E, et al. Bleeding time in patients with cirrhosis: relation with degree of liver failure and clotting abnormalities. C.A.L.C. Group. Coagulation Abnormalities in Cirrhosis Study Group. J Hepatol. 1994;20(4):531–6.CrossRefGoogle Scholar
  17. 17.
    Boberg KM, Brosstad F, Egeland T, Egge T, Schrumpf E. Is a prolonged bleeding time associated with an increased risk of hemorrhage after liver biopsy? Thromb Haemost. 1999;81:378–81.CrossRefGoogle Scholar
  18. 18.
    Cattaneo M, Tenconi PM, Alberca I, et al. Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis. Thromb Haemost. 1990;64(3):358–60.CrossRefGoogle Scholar
  19. 19.
    de Franchis R, Arcidiacono PG, Carpinelli L, et al. Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: a multicenter, double-blind study. New Italian Endoscopic Club. Hepatology. 1993;18(5):1102–7.CrossRefGoogle Scholar
  20. 20.
    Wong AY, Irwin MG, Hui TW, et al. Desmopressin does not decrease blood loss and transfusion requirements in patients undergoing hepatectomy. Can J Anaesth. 2003;50(1):14–20.CrossRefGoogle Scholar
  21. 21.
    Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology. 2006;44:53–61.CrossRefGoogle Scholar
  22. 22.
    McVay PA, Toy PT. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. Am J Clin Pathol. 1990;94:747–53.CrossRefGoogle Scholar
  23. 23.
    Cobb WS, Heniford BT, Burns JM, Carbonell AM, Matthews BD, Kercher KW. Cirrhosis is not a contraindication to laparoscopic surgery. Surg Endosc. 2005;19:418–23.CrossRefGoogle Scholar
  24. 24.
    Inabnet WB, Deziel DJ. Laparoscopic liver biopsy in patients with coagulopathy, portal hypertension, and ascites. Am Surg. 1995;61:603–6.PubMedGoogle Scholar
  25. 25.
    Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci. 1981;26:388–93.CrossRefGoogle Scholar
  26. 26.
    Segal JB, Dzik WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion. 2005;45:1413–25.CrossRefGoogle Scholar
  27. 27.
    Huntington JA. Mechanisms of glycosaminoglycan activation of the serpins in hemostasis. J Thromb Haemost. 2003;1:1535–49.CrossRefGoogle Scholar
  28. 28.
    Kovacs MH, Wong A, MacKinnon K, et al. Assessment of the validity of the INR system for patients with liver impairment. Thromb Haemost. 1994;71:727–30.CrossRefGoogle Scholar
  29. 29.
    Denson KWE, Reed SV, Haddon ME, et al. Comparative studies of rabbit and human recombinant tissue factor reagents. Thromb Res. 1999;94:255–61.CrossRefGoogle Scholar
  30. 30.
    Kar R, Kar SS, Sarin SK. Hepatic coagulopathy-intricacies and challenges; a cross-sectional descriptive study of 110 patients from a superspecialty institute in North India with review of literature. Blood Coagul Fibrinolysis. 2013;24(2):175–80.CrossRefGoogle Scholar
  31. 31.
    Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor liver. Gastroenterology. 2003;124:91–6.CrossRefGoogle Scholar
  32. 32.
    Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33:4–15.CrossRefGoogle Scholar
  33. 33.
    Tripodi A, Salerno F, Chantarangkul V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology. 2005;41:553–8.CrossRefGoogle Scholar
  34. 34.
    Bevers EM, Comfurius P, Zwaal RF. Platelet procoagulant activity: physiological significance and mechanisms of exposure. Blood Rev. 1991;5:146–54.CrossRefGoogle Scholar
  35. 35.
    Tripodi A, Primignani M, Chantarangkul V, et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology. 2006;44:440–5.CrossRefGoogle Scholar
  36. 36.
    Wong F. The use of TIPS in chronic liver disease. Ann Hepatol. 2006;5:5–15.CrossRefGoogle Scholar
  37. 37.
    Jabbour N, Zajko A, Orons P, Irish W, Fung JJ, Selby RR. Does transjugular intrahepatic portosystemic shunt (TIPS) resolve thrombocytopenia associated with cirrhosis? Dig Dis Sci. 1998;43:2459–62.CrossRefGoogle Scholar
  38. 38.
    Ramsey G. Treating coagulopathy in liver disease with plasma transfusions or recombinant factor VIIa: an evidence-based review. Best Pract Res Clin Haematol. 2006;19(1):113–26.CrossRefGoogle Scholar
  39. 39.
    Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology. 2004;127:1123–30.CrossRefGoogle Scholar
  40. 40.
    Shami VM, Caldwell SH, Hespenheide EE, et al. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl. 2003;9:138–43.CrossRefGoogle Scholar
  41. 41.
    Argo CK, Balogun RA. Blood products, volume control, and renal support in the coagulopathy of liver disease. Clin Liver Dis. 2009;13:73–85.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Rakhee Kar
    • 1
  1. 1.Department of PathologyJawaharlal Institute of Postgraduate Medical Education and ResearchPuducherryIndia

Personalised recommendations